Starling Oncology enters USD 25 million revolving credit facility with Gemino Healthcare Finance
STLN•Fees and default terms
A default rate adds 5%. The early termination fee steps down from 3% to 1% of commitments over the term.
Pricing, maturity and security
The facility matures on Aug. 20, 2029. Borrowings are priced at Term SOFR + 3.95% with a 2% Term SOFR floor.
The loan is secured by a first-priority lien on substantially all of SOM’s collateral, and availability is tied to an accounts receivable borrowing base.
Revolving credit facility details
Starling Oncology subsidiary SOM entered a revolving loan agreement with Gemino Healthcare Finance’s SLR Healthcare ABL for up to USD 25 million.
USD 4.75 million was outstanding at closing on Aug. 21, 2026. Proceeds are earmarked for working capital and general corporate purposes.
